Ensoma
Boston, US · Founded 2019 · 19 known investors
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
Founders & leadership
Board
Investors · 19
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$219.6M disclosed across 3 of 5 rounds · 2021–2025
- $50MSeries B ExtensionMay 2023 · 2 sources
5AM Ventures, Alexandria Venture Investments, Arix Bioscience, Bill & Melinda Gates Foundation, Bioluminescence Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime Capital, Fred Hutchinson Cancer Center, Kite, a Gilead Company, Mirae Asset, Qatar Investment Authority (QIA), Solasta Ventures, SymBiosis, Takeda Ventures, Viking Global Investors
Source ↗ - Undisclosed amountSeries BJan 2023Source ↗
▶$129MraisedMay 2023 · 22 investors · BiotechnologyRule 506(b)
- Paula SoteropoulosDirector
- Nihal SinhaDirector
- Emile NuwaysirExecutive Officer, Director
- Kush M ParmarDirector
- Kouki HarasakiDirector
- Mark ChinDirector
- Albert SeymourDirector
- Offering amount
- $129M
- Amount sold
- $129M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$40.5MraisedFeb 2021 · 11 investors · BiotechnologyRule 506(b)
- Kush ParmarExecutive Officer, Director
- Paula SoteropoulosDirector
- Albert SeymourDirector
- Stephen KnightDirector
- Offering amount
- $70.5M
- Amount sold
- $40.5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapyfiercebiotech.com · Aug 2026Frequently asked questions
- What does Ensoma do?
- Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.
- Who are Ensoma's investors?
- Ensoma's investors include 5AM Ventures, Aju IB Invesment Corporation, Catalio Capital Management, LP, Delos Capital, F-Prime Capital, Solasta Ventures, Alexandria, Arix Bioscience and 6 more.
- How much funding has Ensoma raised?
- Ensoma has disclosed $219.6M raised across 3 of its 5 known rounds.
- Where is Ensoma headquartered?
- Ensoma is headquartered in Boston, US.